Cart
sales@molnova.com
GNE-317
CAS No. 1394076-92-6
GNE-317 ( GNE317 )
Catalog No. M11644 CAS No. 1394076-92-6
GNE-317 (GNE317) is a potent, brain penepenetrant, dual PI3K/mTOR inhibitor having physicochemical properties predictive of low efflux by P-gp and BCRP.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 42 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 200 | In Stock |
|
| 50MG | 331 | In Stock |
|
| 100MG | 410 | In Stock |
|
| 200MG | 601 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGNE-317
-
NoteResearch use only, not for human use.
-
Brief DescriptionGNE-317 (GNE317) is a potent, brain penepenetrant, dual PI3K/mTOR inhibitor having physicochemical properties predictive of low efflux by P-gp and BCRP.
-
DescriptionGNE-317 (GNE317) is a potent, brain penepenetrant, dual PI3K/mTOR inhibitor having physicochemical properties predictive of low efflux by P-gp and BCRP; inhibits the cell proliferation of GBM6, 10, 22, and 84 with IC50 of 0.59, 0.72, 0.26, and 3.49 uM, respectively; markedly inhibits the PI3K pathway in mouse brain, causing 40% to 90% suppression of the pAkt and pS6 signals, significantly inhibits tumor growth in orthotopic models of glioblastoma multiforme (GBM).
-
SynonymsGNE317
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1394076-92-6
-
Formula Weight414.48
-
Molecular FormulaC19H22N6O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 20 mg/mL
-
SMILESNC1=NC=C(C2=NC(N3CCOCC3)=C4C(C=C(C5(OC)COC5)S4)=N2)C=N1
-
Chemical Name2-Pyrimidinamine, 5-[6-(3-methoxy-3-oxetanyl)-7-methyl-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Salphati L, et al. Clin Cancer Res. 2012 Nov 15;18(22):6239-48.
2. Lewis Phillips GD, et al. Breast Cancer Res Treat. 2017 Aug;164(3):581-591.
3. Becker CM, et al. Neuro Oncol. 2015 Sep;17(9):1210-9.
2. Lewis Phillips GD, et al. Breast Cancer Res Treat. 2017 Aug;164(3):581-591.
3. Becker CM, et al. Neuro Oncol. 2015 Sep;17(9):1210-9.
molnova catalog
related products
-
Palosuran hydrochlor...
Palosuran is a new potent and specific antagonist of the human UT receptor with an IC50 of 3.6±0.2 nM.
-
TGX-221
A potent, selective PI3K p110β inhibitor with IC50 of 8.5 nM.
-
Gedatolisib
A highly potent, selective, dual PI3K/mTOR inhibitor.
